Expression And Clinical Significance Of Serum MSMB In Prostate Cancer Patients

Objective:To study the association between MSMB and prostate cancer progression and its clinical application value by detecting serum MSMB in prostate cancer patients, and to provide new markers, theoretical basis and research basis for the diagnosis of prostate cancer and malignant behavior assessment.Methods:This study included164subjects. Serum MSMB was detected by ELISA technique in97cases of prostate cancer (test group) and67cases of benign prostatic hyperplasia (control group). The discrepancy of serum MSMB between test group and control group was compared, and the discrepancy of serum MSMB in prostate cancer patients was also analysed among tumor grades (Gleason score), clinical stages and different levels of PSA.Results:ELISA detecting showed that the concentration of serum MSMB in prostate cancer patients [(6.52±2.99) ng/mL] was much lower than that in benign prostatic hyperplasia patients[(23.40±15.37) ng/mL](P=0.000).Moreover, the concentrations of serum MSMB in prostate cancer patients were (8.72±1.06) ng/mL.(6.91±1.62) ng/mL.(2.21±1.55) ng/mL in clinical stages≤T2a、=T2b、≥T2c, respectively (P<0.05); the concentrations of serum MSMB in prostate cancer patients were (8.70±1.35) ng/mL.(6.31±0.78) ng/mL、(2.02±1.31) ng/mL in Gleason score≤6、=7、≥8, respectively (P<0.05), which showed that the concentrations of serum MSMB in prostate cancer patients were much more different in clinical stages and tumor grades.However, the concentrations of serum MSMB in prostate cancer patients were (6.52±2.86) ng/mL.(7.87±2.26) ng/mL.(5.78±3.23) ng/mL in PSA<10ng/mL.(10-20) ng/mL.>20ng/mL, respectively (P=0.052), which showed that no statistical significance was found on the concentrations of serum MSMB in prostate cancer patients with different levels of PSA.Conclusions:Serum MSMB has significant diagnostic value in the patients with prostate cancer, and it is claimed to be a potential biomarker in the diagnosis of prostate cancer. The concentration of serum MSMB in prostate cancer patients was much lower than that in benign prostatic hyperplasia patients, and with the T stage and Gleason score of prostate cancer increasing, the concentration of serum MSMB is reducing. Detecting serum MSMB may give an idea about the invasive potential and malignancy of prostate cancer, and may estimate the prognosis of prostate cancer.